denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Scientific Program
Session: RNA in Normal and Malignant Hematopoiesis
Hematology Disease Topics & Pathways:
Leukemia, AML, Diseases, CLL, CML, Non-Biological, CMML, Therapies, MDS, MPN, Biological Processes, Polycythemia vera, Technology and Procedures, thrombocythemia, epigenetics, Lymphoid Malignancies, Myeloid Malignancies, genomics, genetic profiling, immune mechanism, RNA sequencing, pathogenesis, pathways, signal transduction
Session: RNA in Normal and Malignant Hematopoiesis
Hematology Disease Topics & Pathways:
Leukemia, AML, Diseases, CLL, CML, Non-Biological, CMML, Therapies, MDS, MPN, Biological Processes, Polycythemia vera, Technology and Procedures, thrombocythemia, epigenetics, Lymphoid Malignancies, Myeloid Malignancies, genomics, genetic profiling, immune mechanism, RNA sequencing, pathogenesis, pathways, signal transduction
Saturday, December 5, 2020, 11:55 AM-12:00 PM
Disclosures: Abdel-Wahab: Merck: Consultancy; Envisagenics Inc.: Current equity holder in private company; H3 Biomedicine Inc.: Consultancy, Research Funding; Janssen: Consultancy.
OffLabel Disclosure: I will likely discuss the use of splicing modulatory compounds as well as oligonucleotides in the treatment of hematologic malignancies.